Gene Therapy Oncology Insight: Pipeline Assessment, Industry Trend and Competitive Landscape 2015 adds “Gene Therapy Oncology Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape”to its store.


DelveInsight's Report: Gene Therapy Oncology Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape provides the information across the gene therapy value chain covering gene therapy profiles core insights, pre-clinical data, clinical data, technology details, funding and licensing opportunities. The Gene Therapy Oncology Report provides the target gene name, localization of gene, molecular function of target with descriptive mechanism of action. Using the propriety DelveInsight Competitive Matrix models, the report also provides the first in class market analytics providing predictive analysis of early market winners of the clinical therapies and pre-clinical therapies in a demographic presentation view.Complete report available @ .

Report facts

DelveInsight Gene Therapy Oncology Report: "Gene Therapy Oncology Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape" provides in depth insights into the Oncology gene therapy. It has covered 85+ gene therapies covering 60+ Pharmaceutical companies. Studies are performed for approximately 80+ specific indications under Oncology. The Companies are utilizing 34 different technology platforms which have its own uniqueness and robustness. The Report is also giving insights about the vectors usage in Gene therapy which is approximately 60% for viral vectors, 23% for RNAi therapeutics and 17% for Non Viral vectors. The Report is also giving early winners of the Oncology gene therapy market using DelveInsight proprietary Matrix Model

Reports Highlights:

  • Global Gene Therapy Overview & Pipeline Insights
  • Trends in gene therapy partnering deals
  • Current Prominent Research Areas and Key Players
  • Companies Targeting Prominent Therapeutic Areas
  • Number of Gene Therapies in Clinical Trials
  • Number of Gene Therapies by Vectors used
  • Technology and their innovative Companies
  • Early Market Winners for Gene Therapy


  • A snapshot of the global Gene therapy market scenario, market trends & drivers, manacles of gene therapy.
  • A review of the marketed Gene therapy products and marketing status
  • Coverage of global gene therapies under development across the globe covering territories
  • Competitive landscape of investigational products for key players and key therapy areas.
  • The Gene Therapy report covers the product description, stage of development, licensors & collaborators, Development partner and Technology information
  • The Report also provides the pre-clinical and clinical outcomes of the gene therapies
  • The Report has covered the vector used, target genes, localization of gene and detailed mechanism of action
  • Report has highlighted the licensing opportunities and funding details for gene therapies
  • The report also gives the information of dormant and discontinued pipeline projects
  • Market Analytics of Gene Therapies using DelveInsight Propriety Model.

Inquire for discount on this report @ .

Reason to Buy

  • Complete Market and Pipeline intelligence and complete understanding over therapeutics development for gene therapy
  • Devise corrective measures for pipeline projects by understanding Therapy area specific gene therapies
  • Developing strategic initiatives to support your gene therapy development activities.
  • Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
  • Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Evaluate the marketing and pipeline strategy for gene therapies and their Funding availabilities.
  • Identifying the upcoming leaders in the gene therapy market in the coming years.
  • Getting a first mover advantage by identifying the early market winners for clinical and preclinical gene therapies.